Literature DB >> 23286334

MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia.

Gerardo Ferrer1, Alfons Navarro, Kate Hodgson, Marta Aymerich, Arturo Pereira, Tycho Baumann, Mariano Monzo, Carol Moreno, Emili Montserrat.   

Abstract

Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune hemolytic anemia (AIHA). However, the mechanisms governing the association between CLL and AIHA are poorly understood. MicroRNAs (miRNAs) have been associated with different clinico-biological forms of CLL and are also known to play a substantial role in autoimmunity. However, there are no studies correlating miRNA expression with the likelihood that patients with CLL will develop AIHA. In this study, we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs. Interestingly, two of these miRNAs (i.e. miR-20a and miR-146b-5p) are involved in autoimmune phenomena, and one (i.e. miR-146b-5p) in both autoimmunity and CLL. Furthermore, we demonstrated that miR-146b-5p modulates CD80, a molecule associated with the B-T-cell synapse and in restoration of the antigen presenting cell capacity of CLL cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286334     DOI: 10.3109/10428194.2012.763123

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

2.  Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren's Syndrome.

Authors:  V C Gourzi; E K Kapsogeorgou; N C Kyriakidis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2015-07-21       Impact factor: 4.330

3.  MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells.

Authors:  Guanghui Cui; Mingwei Cui; Yuhang Li; Youguang Liang; Weihao Li; Haizhou Guo; Song Zhao
Journal:  Tumour Biol       Date:  2014-06-04

4.  miR-150 regulates B lymphocyte in autoimmune hemolytic anemia/Evans syndrome by c-Myb.

Authors:  Limin Xing; Wenyan Xu; Yingying Qu; Manjun Zhao; Hongli Zhu; Hong Liu; Huaquan Wang; Xin Su; Zonghong Shao
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

5.  Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.

Authors:  O Fortunato; M Boeri; M Moro; C Verri; M Mensah; D Conte; L Caleca; L Roz; U Pastorino; G Sozzi
Journal:  Cell Death Dis       Date:  2014-12-11       Impact factor: 8.469

6.  Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.

Authors:  M Zhang; Z Luo; H Liu; C M Croce; T R Burke; D P Bottaro
Journal:  Leukemia       Date:  2013-10-31       Impact factor: 11.528

7.  Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression.

Authors:  J Lin; J-C Ma; J Yang; J-Y Yin; X-X Chen; H Guo; X-M Wen; T-J Zhang; W Qian; J Qian; Z-Q Deng
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

Review 8.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

9.  miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.

Authors:  A Navarro; S Pairet; A Álvarez-Larrán; A Pons; G Ferrer; R Longarón; C Fernández-Rodríguez; L Camacho; M Monzó; C Besses; B Bellosillo
Journal:  Blood Cancer J       Date:  2016-03-18       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.